ArticleClinical and translational radiation oncology2024

Dosimetric feasibility analysis and presentation of an isotoxic dose-escalated radiation therapy concept for glioblastoma used in the PRIDE trial (NOA-28; ARO-2022-12).

Raphael Bodensohn et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.